Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339415 · ClinicalTrials.gov registry record · Phase 2
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
A Phase 2 study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT02339415 is a Phase 2 study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 44 participants.
The verdict
NCT02339415, a Phase 2 study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
Interventions
- DRUG Matching placebo
- DRUG Edoxaban 30mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339415
The ClinicalTrials.gov registry entry for NCT02339415 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT02339415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02339415 about?
NCT02339415 is a clinical study titled "Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease". The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
What is the current status of trial NCT02339415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2015-07. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02339415?
The interventions under investigation include: Matching placebo (DRUG), Edoxaban 30mg daily (DRUG).
Who is sponsoring clinical trial NCT02339415?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.